Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.45 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.43 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CSK | P41240 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7387839 | 1.00 | ALDH1A1 (0.53) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| Hydrochloric Acid SCHEMBL7385556 | 1.00 | ALDH1A1 (0.53) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| SCHEMBL5916451 | 0.98 | ALDH1A1 (0.51) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| SCHEMBL1108340 | 0.98 | ALDH1A1 (0.51) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| SCHEMBL27477965 | 0.98 | ALDH1A1 (0.51) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| SCHEMBL4087293 | 0.91 | PTGS2 (0.50) | ALDH1A1ESR1ESR2PTGS2LTA4H | |
| Hydrochloric Acid SCHEMBL5061884 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| Tyrosine Methyl Ester SCHEMBL919401 | 0.86 | ESR1 (0.61) | ALDH1A1ESR1ESR2SLC7A5LNPEP | |
| Hydrochloric Acid SCHEMBL16060242 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ESR1ESR2SLC7A5PTGS2 | |
| Tyrosine Methyl Ester SCHEMBL945724 | 0.86 | ESR1 (0.61) | ALDH1A1ESR1ESR2SLC7A5LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538182-B2 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070037967-A1 | conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7129327-B2 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1056714-B1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20040081660-A1 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6673347-B1 | CONJUGATED TO POLYMER VIA SCHIFF BASE, HYDRAZONE, OXIME, OR AZOMETHINE COMPOUND; DIAGNOSING TUMORS AND METASTASIS | GRYPHON THERAPEUTICS | 2004-01-06 | — | — | US | disclosed |
| EP-0243929-B1 | Polypeptide and protein derivatives and process for their preparation | OFFORD ROBIN EWART (CH) | 1995-09-27 | — | — | EP | disclosed |
| EP-0243929-A2 | Polypeptide and protein derivatives and process for their preparation | Offord, Robin Ewart (CH) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037967-A1 | conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer | HDGFL3, HCCS, HDGF | ESR1 2997/4885ESR2 1941/4885PTGS2 3308/4885 |
| US-20040081660-A1 | Polypeptide and protein derivatives and process for their preparation | INSRR, GIPR, HM13 | ESR1 4188/4885ESR2 2851/4885PTGS2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.